Press Release

Not for publication in the U.S. Vienna, Austria, Mar 4, 2026

European Congress of Radiology (ECR) 2026, Austria Center Vienna, Hall X5 #513

Siemens Healthineers Presents New Angiography Systems with AI to Aid Precise Embolization Treatment of Liver Cancer

- **Latest innovation in interventional radiology**
- **Automated motion reduction for detailed 3D visualization of vessels and devices like catheters**
- **AI-guided planning for precise treatment of liver cancer patients**

At this year's European Congress of Radiology, Siemens Healthineers is highlighting its latest innovation in the field of interventional radiology. The new angiography platforms Artis genio, Artis icono.explore[1] and Artis icono.vision use artificial intelligence to support the precise embolization treatment of liver cancer[2]. Features include automated motion correction in three-dimensional cone beam computed tomography (CBCT) datasets, software for accurate planning and device navigation, and the new Optiq AI imaging chain for higher image quality at the same dose.

Tumor embolization is an essential form of cancer treatment as it reduces the tumor burden, relieves symptoms and is highly targeted. The procedure, where interventional radiologists block the blood supply to a tumor or deliver drugs only to the tumor's feeding vessels, is performed in a minimally invasive way. Image guidance ensures precise catheter navigation and real-time visualization. Eligible patients benefit from fewer side effects than with systemic treatments like chemotherapy. But embolizations are also complex and require highly personalized planning and treatment precision – both of which are a challenge in times of a growing patient population and a decreasing number of medical staff. With that in mind, Siemens Healthineers has equipped its latest angiography systems Artis genio, Artis icono.explore and vision with AI-powered applications.

Because embolizations require highly detailed imaging on which to base decisions, Siemens Healthineers offers its fully automated software Syngo DynaCT MORE for motion reduction. The use of 3D imaging techniques such as DynaCT alongside 2D imaging enhances the manual assessment of anatomical information and provides a reliable basis for advanced 3D planning and navigation tools. But 3D imaging of

Siemens Healthineers AG
Communications

Siemensstraße 3
91301 Forchheim
Germany

the thorax and abdomen can be compromised by motion artifacts caused by pulsating vessels, heartbeat, or patient breathing, resulting in blurring and reduced detail visibility. Through iterative image reconstruction, Syngo DynaCT MORE provides a realignment of high-contrast structures like vessels and devices, without losing anatomical information. DynaCT datasets that were previously not usable due to patient movement can be restored, potentially reducing the need for repeated scans.

To boost workflow efficiency, Siemens Healthineers has developed the AI-based myEmbolization Guide for its new systems, which automates manual tasks and supports decision-making. The algorithm behind myEmbolization Guide has been trained organ-specifically, so that interventional radiologists can choose a liver, prostate or a flexible general workflow when starting the planning and guidance software. The liver workflow offers precise three-dimensional tumor contouring with a clear target depiction of the tumor and the flexibility to select an extended, consistent treatment zone around it in 3D. The comprehensive vascular map for liver and prostate embolization clearly differentiates feeder from non-feeder vessels, which allows for confident planning and precise navigation in the interventional room. This also applies when treating benign prostate hyperplasia, a non-cancerous enlargement of the prostate gland, with prostatic artery embolization.

The new Artis portfolio is also equipped with the imaging chain Optiq AI. During the image-processing step, an AI-based algorithm reduces the noise introduced by X-ray scatter effects and the imaging system during image formation (such as noise from electronics) in real time. This denoising benefits various two-dimensional imaging modes for better image quality at the same dose.

An intuitive user interface helps workflow efficiency, guiding users through all steps and supporting the interaction between control and exam room.

“Interventional radiology demands precision, and our new Artis portfolio represents a leap towards truly personalized therapy for cancer patients,” said Carsten Bertram, head of Advanced Therapies at Siemens Healthineers. “With artificial intelligence as a key enabler, we aim to empower healthcare professionals to treat more patients more effectively.”

Prof. Dr. med. Frank K. Wacker, president of DeGIR (Deutsche Gesellschaft für Interventionelle Radiologie und minimal-invasive Therapie; German society for interventional radiology and minimally invasive therapy), added: “Any guidance on the workflow greatly improves the learning experience we can provide to our residents, and it also reduces errors and I think standardization helps a lot in delivering reliable patient care.”

[1] Artis icono.vision is an edition of Artis icono
[2] syngo Application Software needed
The products and features mentioned herein are not available in all countries. Their future availability cannot be guaranteed.

A press picture is available here: https://www.siemens-healthineers.com/press/releases/New-Artis-family

Media contact

Kathrin Palder

+49 173 3645319; Kathrin.Palder@siemens-healthineers.com

Visit the Siemens Healthineers Press Center.

Subscribe to our "Medtech matters" newsletter on LinkedIn.

Siemens Healthineers pioneers breakthroughs in healthcare. For everyone. Everywhere. Sustainably. The company is a global provider of healthcare equipment, solutions and services, with activities in more than 180 countries and direct representation in more than 70. The group comprises Siemens Healthineers AG, listed as SHL in Frankfurt, Germany, and its subsidiaries. As a leading medical technology company, Siemens Healthineers is committed to improving access to healthcare for underserved communities worldwide and is striving to overcome the most threatening diseases. The company is principally active in the areas of imaging, diagnostics, cancer care and minimally invasive therapies, augmented by digital technology and artificial intelligence. In fiscal 2025, which ended on September 30, 2025, Siemens Healthineers had approximately 74,000 employees worldwide and generated revenue of around €23.4 billion. Further information is available at siemens-healthineers.com.